1
|
Andersen LL, Huang Y, Urban C, Oubraham L, Winheim E, Stafford C, Nagl D, O'Duill F, Ebert T, Engleitner T, Paludan SR, Krug A, Rad R, Hornung V, Pichlmair A. Systematic P2Y receptor survey identifies P2Y11 as modulator of immune responses and virus replication in macrophages. EMBO J 2023; 42:e113279. [PMID: 37881155 PMCID: PMC10690470 DOI: 10.15252/embj.2022113279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 09/20/2023] [Accepted: 09/29/2023] [Indexed: 10/27/2023] Open
Abstract
The immune system is in place to assist in ensuring tissue homeostasis, which can be easily perturbed by invading pathogens or nonpathogenic stressors causing tissue damage. Extracellular nucleotides are well known to contribute to innate immune signaling specificity and strength, but how their signaling is relayed downstream of cell surface receptors and how this translates into antiviral immunity is only partially understood. Here, we systematically investigated the responses of human macrophages to extracellular nucleotides, focusing on the nucleotide-sensing GPRC receptors of the P2Y family. Time-resolved transcriptomic analysis showed that adenine- and uridine-based nucleotides induce a specific, immediate, and transient cytokine response through the MAPK signaling pathway that regulates transcriptional activation by AP-1. Using receptor trans-complementation, we identified a subset of P2Ys (P2Y1, P2Y2, P2Y6, and P2Y11) that govern inflammatory responses via cytokine induction, while others (P2Y4, P2Y11, P2Y12, P2Y13, and P2Y14) directly induce antiviral responses. Notably, P2Y11 combined both activities, and depletion or inhibition of this receptor in macrophages impaired both inflammatory and antiviral responses. Collectively, these results highlight the underappreciated functions of P2Y receptors in innate immune processes.
Collapse
Affiliation(s)
- Line Lykke Andersen
- Institute of Virology, School of MedicineTechnical University of MunichMunichGermany
| | - Yiqi Huang
- Institute of Virology, School of MedicineTechnical University of MunichMunichGermany
| | - Christian Urban
- Institute of Virology, School of MedicineTechnical University of MunichMunichGermany
| | - Lila Oubraham
- Institute of Virology, School of MedicineTechnical University of MunichMunichGermany
| | - Elena Winheim
- Institute of Immunology, Biomedical CenterLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Che Stafford
- Department of Biochemistry, Gene Center MunichLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Dennis Nagl
- Department of Biochemistry, Gene Center MunichLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Fionan O'Duill
- Department of Biochemistry, Gene Center MunichLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Thomas Ebert
- Department of Biochemistry, Gene Center MunichLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Thomas Engleitner
- Institute of Molecular Oncology and Functional Genomics, School of MedicineTechnical University of MunichMunichGermany
| | - Søren Riis Paludan
- Department of BiomedicineAarhus UniversityAarhusDenmark
- Center of immunology of viral infection (CiViA)Aarhus UniversityAarhusDenmark
| | - Anne Krug
- Institute of Immunology, Biomedical CenterLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Roland Rad
- Institute of Molecular Oncology and Functional Genomics, School of MedicineTechnical University of MunichMunichGermany
| | - Veit Hornung
- Department of Biochemistry, Gene Center MunichLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Andreas Pichlmair
- Institute of Virology, School of MedicineTechnical University of MunichMunichGermany
- Center of immunology of viral infection (CiViA)Aarhus UniversityAarhusDenmark
- German Center for Infection Research (DZIF), Munich Partner SiteMunichGermany
| |
Collapse
|
2
|
Foret-Lucas C, Figueroa T, Bertin A, Bessière P, Lucas A, Bergonnier D, Wasniewski M, Servat A, Tessier A, Lezoualc’h F, Volmer R. EPAC1 Pharmacological Inhibition with AM-001 Prevents SARS-CoV-2 and Influenza A Virus Replication in Cells. Viruses 2023; 15:319. [PMID: 36851533 PMCID: PMC9965159 DOI: 10.3390/v15020319] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 01/17/2023] [Accepted: 01/19/2023] [Indexed: 01/24/2023] Open
Abstract
The exceptional impact of the COVID-19 pandemic has stimulated an intense search for antiviral molecules. Host-targeted antiviral molecules have the potential of presenting broad-spectrum antiviral activity and are also considered as less likely to select for resistant viruses. In this study, we investigated the antiviral activity exerted by AM-001, a specific pharmacological inhibitor of EPAC1, a host exchange protein directly activated by cyclic AMP (cAMP). The cAMP-sensitive protein, EPAC1 regulates various physiological and pathological processes but its role in SARS-CoV-2 and influenza A virus infection has not yet been studied. Here, we provide evidence that the EPAC1 specific inhibitor AM-001 exerts potent antiviral activity against SARS-CoV-2 in the human lung Calu-3 cell line and the African green monkey Vero cell line. We observed a concentration-dependent inhibition of SARS-CoV-2 infectious viral particles and viral RNA release in the supernatants of AM-001 treated cells that was not associated with a significant impact on cellular viability. Furthermore, we identified AM-001 as an inhibitor of influenza A virus in Calu-3 cells. Altogether these results identify EPAC1 inhibition as a promising therapeutic target against viral infections.
Collapse
Affiliation(s)
- Charlotte Foret-Lucas
- Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE, IHAP, UMR 1225, 31300 Toulouse, France
| | - Thomas Figueroa
- Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE, IHAP, UMR 1225, 31300 Toulouse, France
| | - Alexandre Bertin
- Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE, IHAP, UMR 1225, 31300 Toulouse, France
| | - Pierre Bessière
- Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE, IHAP, UMR 1225, 31300 Toulouse, France
| | - Alexandre Lucas
- Institute of Metabolic and Cardiovascular Diseases, INSERM, Université de Toulouse, UMR 1297-I2MC, 31432 Toulouse, France
| | - Dorian Bergonnier
- Institute of Metabolic and Cardiovascular Diseases, INSERM, Université de Toulouse, UMR 1297-I2MC, 31432 Toulouse, France
| | - Marine Wasniewski
- Nancy Laboratory for Rabies and Wildlife, ANSES, Lyssavirus Unit, 54220 Malzéville, France
| | - Alexandre Servat
- Nancy Laboratory for Rabies and Wildlife, ANSES, Lyssavirus Unit, 54220 Malzéville, France
| | - Arnaud Tessier
- Nantes Université, CNRS, CEISAM, UMR 6230, 44000 Nantes, France
| | - Frank Lezoualc’h
- Institute of Metabolic and Cardiovascular Diseases, INSERM, Université de Toulouse, UMR 1297-I2MC, 31432 Toulouse, France
| | - Romain Volmer
- Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE, IHAP, UMR 1225, 31300 Toulouse, France
| |
Collapse
|